State strategies and the geopolitics of the global knowledge economy: China, India and the case of regenerative medicine

Geopolitics

Volumn 14, Issue 1, 2009, Pages 47-78

  Salter, Brian ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; GEOPOLITICS; GLOBAL ECONOMY; GLOBALIZATION; HEGEMONY; INTERNATIONAL RELATIONS; STATE ROLE; STRATEGIC APPROACH;

ASIA; CHINA; EURASIA; FAR EAST; INDIA; SOUTH ASIA;

EID: 61549133622     PISSN: 14650045     EISSN: 15573028     Source Type: Journal    
DOI: 10.1080/14650040802578666     Document Type: Article

References (140)

1. J. Agnew, Geopolitics: Revisioning World Politics (New York: Routledge 1998).
2. D. Scott, 'The Great Power Game between India and China: The 'Logic of Geography', Geopolitics 13/1 (2008) pp. 1-26.
3. US Food and Drug Administration, Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (Washington, DC: US Food And Drug Administration 2004) p. 8.
4. W. A. Haseltine, 'Regenerative Medicine: An Overview', Journal of Regenerative Medicine 4 (2003) pp. 15-18.
5. US Department of Health and Human Services, 2020: A New Vision. A Future for Regenerative Medicine (Washington, DC: US Department of Health and Human Services 2006), available at .
6. N. Brown, Hope against Hype: Accountability in Biopasts, Presents and Futures. Science Studies. 16/2 (2003) pp. 3-21.
7. N. Brown and M. Michael, 'A Sociology of Expectations: Retrospecting Prospects and Prospecting Retrospects', Technology Analysis and Strategic Management 15/1 (2003) pp. 3-18.
8. N. Brown, B. Rappert, and A. Webster (eds.), Contested Futures: A Sociology of Prospective Technoscience (Aldershot: Ashgate 2000).
9. US Academies of Science, Commission on Life Sciences, Stem Cells and the Future of Regenerative Medicine (Washington, DC: National Academy Press 2002).
10. US Department of Health and Human Services, 2020: A New Vision. A Future for Regenerative Medicine (Washington, DC: US Department of Health and Human Services 2006), available at .
11. British Standards Institution, Guidance on Codes of Practice, Standardised Methods and Regulations for Cell-Based Therapeutics from Basic Research to Clinical Application, PAS 83 (London: British Standards Institution 2006), available at , accessed 3 May 2007.
12. Biophoenix, Opportunities in Stem Cell Research and Commercialisation (London: Business Insights 2006) p. 80.
13. J. Agnew, 'The New Global Economy: Time-Space Compression, Geopolitics, and Global Uneven Development', Journal of World systems Research 7/2 (2001) pp. 133-54.
14. US Department of Health and Human Services, 2020: A New Vision. A Future for Regenerative Medicine (Washington, DC: US Department of Health and Human Services 2006), available at .
15. UK Stem Cell Initiative, Report and Recommendations (London: Department of Health 2005) p. 5.
16. German Federal Ministry of Education and Research (BMBF), Regenerative Technologies for Medicine and Biology - Contributions for a Strategic Funding Concept (Berlin: Capgemini Deutschland 2007), available at , accessed 9 May 2007.
17. M. Beeson, 'American Hegemony and Regionalism: The Rise of East Asia and the End of the Asia-Pacific', Geopolitics 11/4 (2006) pp. 541-560.
18. C. Cookson, 'Country Report: China', Financial Times (17 June 2005) p. 1.
19. UK Stem Cell Initiative (note 15) p. 5.
20. T. V. Padma, 'India Plans Stem Cell Initiative', SciDevNet (13 Jan. 2005), available at , accessed 9 May 2007.
21. H. Gottweis and R. Triendl, 'South Korean Policy Failure and the Hwang Debacle', Nature Biotechnology 24 (2006) pp. 141-143.
22. T. G. Kim, '$450 Million Budget Set for Stem Cell Research', The Korean Times (29 May 2006).
23. Elias, 'Singapore Woos Top Scientists', ABC News (29 June 2006), available at .
24. K. Holden and D. Demeritt, 'Democratising Science? The Politics of Promoting Biomedicine in Singapore's Developmental State', Environment and Planning D: Society and Space 26/1 (2008) pp. 68-86.
25. P. Cerny, The Changing Architecture of Politics: Structure, Agency and the Future of the State (London: Sage 1990).
26. P. Cerny, 'Paradoxes of the Competition State: The Dynamics of Political Globalisation', Government and Opposition 32/2 (1997) pp. 251-74.
27. C. Hay, 'Re-Stating Politics, Re-Politicising the State: Neo-Liberalism, Economic Imperatives and the Rise of the Competition State', Political Quarterly 75/1 (2004) pp. 38-50.
28. J. Hirsch, 'From the Fordist to the Post-Fordist State', in B. Jessop (ed.), The Politics of Flexibility: Restructuring State and Industry in Britain, Germany and Scandinavia (Aldershot: Edward Elgar 1991).
29. B. Jessop, The Future of the Capitalist State (Oxford: Polity Press 2002).
30. D. Messner, The Network Society: Economic Development and International Competitiveness as Problems of Social Governance (London: Frank Cass 1997).
31. J. Pierre (ed.), Debating Governance (Oxford: Oxford University Press 2000).
32. C. Dahlman and J. Aubert, China and the Knowledge Economy: Seizing the 21st Century (Washington, DC: World Bank 2001) p. 43, available at , accessed 4 June 2007.
33. R. Nelson (ed.), National Innovation Systems: A Comparative Analysis (Oxford: Oxford University Press 1993).
34. M. Mazzucato and G. Dosi (eds.), Knowledge Accumulation and Industry Evolution (Cambridge: Cambridge University Press 2006).
35. B. T. Asheim and M.S. Gertler, 'The Geography of Innovation: Regional Innovation Systems', in J. Fagerberg, D. C. Mowery and R. R. Nelson (eds.), The Oxford Handbook of Innovation (Oxford: Oxford University Press 2004).
36. P. Cooke, 'The Evolution of Biotechnology in Three Continents: Schumpeterian or Penrosian?' (Editorial), European Planning Studies 11/7 (2003) pp. 757-763.
37. P. Cooke, 'Regional Knowledge Capabilities, Embeddedness of Firms and Industry Organisation: Bioscience Megacentres and Economic Geography', European Planning Studies 11/7 (2004) pp. 625-641.
38. D. Hart, 'Private Technological Capabilities as Products of National Innovation Systems: Four Ways of Looking at the State', Science and Public Policy 29/3 (2002) pp. 181-188.
39. A. Hansen, 'Biotechnology Regulation: Limiting or Contributing to Biotech Development?', New Genetics and Society 20/3 (2001) pp. 255-271.
40. P. Laredo and P. Mustar, 'General Conclusion: Three Major Trends in Research and Innovation Policies', in P. Laredo and P. Mustar (eds.), Research and Innovation Policies in the Global Economy: An International Comparative Perspective (Cheltenham: Edward Elgar 2001).
41. M. Benner and H. Löfgren, 'The Bio-Economy and the Competition State: Transcending the Dichotomy between Coordinated and Liberal Market Economies', New Political Science 29/1 (2007) pp. 77-95.
42. British Standards Institution (note 11).
43. C. Prescott, Investing in Stem Cells: A Venture Capital Perspective Avlar Bioventures, presentation to the East of England Stem Cell Network, Cambridge, 8 March 2005.
44. In September 2006 the Roslin Cells Centre in Scotland launched a public-private initiative that brings together the Roslin Institute, Scottish Enterprise, Edinburgh University and the Scottish National Blood Transfusion Service to develop human stem cell lines that will be sold worldwide for drug testing and medicines development. Interestingly, the Centre is described as 'the first step in a supply chain to support the development of the wider stem cell sector in Scotland, providing cells that can be used by academics, NHS Scotland and commercial companies' (BBC News 2006).
45. This figure is an adapted version of one by Perrin 2005. N. Perrin, The Global Commercialisation of Stem Cell Research (London: UK Trade and Investment 2005), available at , accessed 24 May 2007.
46. H. Rothman and A. Kraft, 'Downstream and into Deep Biology: Evolving Business Models in 'Top Tier' Genomics Companies', Journal of Commercial Biotechnology 12/2 (2006) pp. 86-98.
47. J. Agnew, Hegemony: The New Shape of Global Power (Philadelphia: Temple University Press 2005).
48. R. P. Applebaum and J. Henderson (eds.), States and Development in the Asian Pacific Rim (Newbury Park, CA: Sage 1992).
49. G. Hawes and H. Liu, 'Explaining the Dynamics of the Southeast Asian Political Economy: State, Society and the Search for Economic Growth', World Politics 45/4 (1993) pp. 629-660.
50. Z. Onis, 'The Logic of the Developmental State', Comparative Politics 24/1 (1991) pp. 109-126.
51. A. Amsden, Asia's Next Giant. South Korea and Late Industrialisation (New York: Oxford University Press 1989).
52. C. Johnson, MITI and the Japanese Miracle (Stanford: Stanford University Press 1982).
53. R. Wade, Governing the Market: Economic Theory and the Role of Government in Asian Industrialisation (Princeton: Princeton University Press 1990).
54. L. Weiss, 'Developmental States in Transition: Adapting, Dismantling, Innovating, Not 'Normalising'', The Pacific Review 13/1 (2000) pp. 21-55, 29.
55. R. Wade, 'What Strategies Are Viable for Developing Countries Today? The World Trade Organisation and the Shrinking of 'Development Space'. Review of International Political Economy 10/4 (2003) pp. 621-644.
56. M. Mann, 'Has Globalisation Ended the Rise and Rise of the Nation State?', Review of International Political Economy 4/3 (1997) pp. 472-496.
57. R. Wade, National Diversity And Global Capitalism (Cornell: Cornell University Press 1996).
58. L. Weiss, The Myth of the Powerless State (Cornell: Cornell University Press 1998).
59. Y. T. Kim, 'Neoliberalism and the Decline of the Developmental State', Journal of Contemporary Asia 29/4 (1999) pp. 441-462.
60. Y. Wu, 'Rethinking the Taiwanese Developmental State', The China Quarterly 177 (2004) pp. 91-114.
61. J. Wong, 'Re-Making the Developmental State in Taiwan: The Challenges of Biotechnology', International Political Science Review 26 (2005) pp. 169-190.
62. J. Wong, 'Re-Making the Developmental State' (note 61) pp. 169-190.
63. L. Weiss and J. Hobson, States and Economic Development: A Comparative Historical Analysis (London: Polity Press 1995).
64. M. S. Haque, 'Governance and Bureaucracy in Singapore: Contemporary Reforms and Implications', International Political Science Review 25/2 (2004) pp. 227-240.
65. J. Wong, 'The Adaptive Developmental State in East Asia', Journal of East Asian Studies 4 (2004) pp. 345-362.
66. J. Wong, 'Re-Making the Developmental State' (note 61) pp. 169-190.
67. C. S. Lee and A. Schrank, 'Incubating Innovation or Cultivating Corruption? The Development State and the Life Sciences in Asia', Social Forces (forthcoming).
68. J. Minns, 'Of Miracles and Models: The Rise and Decline of the Developmental State in South Korea', Third World Quarterly 22/6 (2001) pp. 1025-1043.
69. T. Saich, The changing role of government? Background Note for the World Bank Report on China's 11th Five Year Plan (2004) p. 4, available at , accessed 2 June 2007.
70. R. Baum and A. Shevchenko, 'The State of the State', in M. Goldman and R. MacFarquar (eds.), The Paradox of Reform of China's Post-Mao Reforms (Cambridge MA: Harvard University Press 1999).
71. T. Saich, 'Negotiating the State: The Development of Social Organisations in China', The China Quarterly 161 (2000) pp. 124-141.
72. T. Saich, 'Reform and the Role of the State in China', in R. Benewick et al. (eds.), Asian Politics in Development (London: Frank Cass 2003).
73. Dahlman and Aubert (note 32) p. 43.
74. V. Chibber, Locked in Place: State Building and Late Industrialisation in India (Princeton: Princeton University Press 2003).
75. World Bank, India: Five Years of Stabilization and Reform and the Challenges Ahead (New York: World Bank 1997).
76. C. Dahlman and A. Utz, India and the Knowledge Economy: Leveraging Strengths and Opportunities (Washington, DC: World Bank 2006), available at , accessed 4 June 2007.
77. A. Winters and S. Yusuf, Dancing with Giants: China, India and the Global Economy (Singapore: Institute of Policy Studies 2007).
78. This section draws on data from two articles: B. Salter, M. Cooper, and A. Dickins, 'China and the Global Stem Cell Bioeconomy: An Emerging Political Strategy?', Regenerative Medicine 1/5 (2006) pp. 671-683
79. and B. Salter, M. Cooper, A. Dickins, and V. Cardo, 'Stem Cell Science in India: Emerging Economies and the Politics of Globalisation', Regenerative Medicine 2/1 (2007) pp. 75-79.
80. Dahlman and Aubert (note 32) p. 43.
81. OECD, China Will Become World's Second Highest Investor in R & D by End of 2006 Finds OECD (Paris: OECD 2006), available at <2649_34273_37770522_1_1_1_1,00.html>, accessed 5 June 2007.
82. K. Bound, India: The Uneven Innovator (London: Demos 2007) p. 12.
83. OECD, OECD Science, Technology and Industry Scoreboard (Paris: OECD 2005) pp. 62-63.
84. R. Shukla, India Science Report: Science Education, Human Resources and Public Attitudes Towards Science and Technology (New Dehli: National Council of Applied Economic Research 2005).
85. M. Sur, 'Breathing Life into Biology', Nature Outlook: India, Nature 436 (28 July 2005) p. 487.
86. K. S. Jayaraman, 'Among the Best', Nature Outlook: India, Nature 436 (28 July 2005) p. 483.
87. NB 2002 figure for South Korea; no 2001 figure available. Source: National Science Board 2006, pp. A2-A43.
88. OECD, OECD Science (note 82) pp. 62-63.
89. National Science Board, Science and Engineering Indicators 2006 Vol. 2 (Arlington, VA: National Science Foundation 2006) pp. A2-A17.
90. Ibid., pp. A2-A33.
91. OECD, OECD Science (note 82) pp. 62-63.
92. Z. Li, J. Zhang, K. Wen, H. Thorsteinsdóttir, U. Quach, P. A. Singer, and A. S. Daar, 'Health Biotechnology in China: Reawakening of a Giant', Nature Biotechnology 22, Supplement (2004) pp. DC13-DC18.
93. National Science Board (note 88) pp. A3-A55.
94. D. Zweig, 'Competing for Talent: China's Strategies to Reverse the Brain Drain', International Labour Review 145/1-2 (2006) pp. 65-89.
95. Department of Trade and Industry, Global Watch Service. Science and Technology Statistics. China, available at , accessed 3 July 2006.
96. U. Hunger, 'Indian IT Entrepreneurs in the US and in India: An Illustration of the 'Brain Gain Hypothesis", Journal of Comparative Public Policy 6/2 (2004) pp. 99-109.
97. W. Arnold, 'Singapore Fills Stem-Cell Void Created by a US Ban', International Herald Tribune. Business (17 Aug. 2006), available at , accessed 4 June 2007.
98. A. D. Levine, 'Research Policy and the Mobility of US Stem Cell Scientists', Nature Biotechnology 24/7 (2006) pp. 865-866.
99. National Science Board (note 88) pp. A5-A41.
100. Ibid.
101. European Patent Office and OECD, Intellectual Property as an Economic Asset: Key Areas in Valuation and Exploitation (Brussels: European Patent Office 2005), available at , accessed 6 June 2007.
102. OECD, OECD Science (note 82) pp. 62-63.
103. R. Florida and D. Smith, 'Venture Capital, Innovation, and Economic Development', Economic Development Quarterly 4 (1990) pp. 345-360.
104. R. Florida and M. Samber, 'Capital and Creative Destruction: Venture Capital, Technological Change, and Economic Development', in M. Gertler and T. Barnes (eds.), The New Industrial Geography: Regions, Regulations and Institutions (London: Routledge 1999).
105. M. Haemmig, The Globalisation of Venture Capital. A Management Study of International Venture Capital Firms (Bern/Stuttgart: Verlag Paul Haupt 2003).
106. P. Drahos, 'Intellectual Property and Human Rights', Intellectual Property Quarterly 3 (1999) pp. 349-371.
107. P. Drahos, 'Developing Countries and International Intellectual Property Standard-Setting', Journal of World Intellectual Property 5 (2002) pp. 765-789.
108. World Intellectual Property Organisation, WIPO Patent Report. Statistics on Worldwide Patent Activity 2006 Edition (Geneva: WIPO 2006) pp. 7, 10, 16.
109. Ibid.
110. Ibid.
111. National Science Board (note 88) pp. A6-A13.
112. Science Business, 'South Korea and China Transform the Geography of Patents', Science Business (14 Feb. 2007).
113. O. Doring, 'Chinese Researchers Promote Biomedical Regulations: What the Motives of the Biopolitical Dawn in China and Where Are They Heading?', Kennedy Institute of Ethics Journal 14/1 (2004) pp. 39-46.
114. Ernst and Young, Progressions 2006. Capturing Global Advantage in the Pharmaceutical Industry (New York: Ernst and Young Global Pharmaceutical Centre 2006) p. 54.
115. M. Kenney, India, China and Offshoring (2004-05) (Berkeley, CA: UC Davis 2005), available at , accessed 6 June 2007.
116. A. Ross, Fast Boat to China: Corporate Flight and the Consequences of Free Trade; Lessons from Shanghai (New York: Pantheon 2006).
117. Ernst and Young (note 113).
118. A. Petryna, 'Ethical Variability: Drug Development and Globalising Clinical Trials', American Ethnologist 32/2 (2005) pp. 183-97.
119. A. T. Kearney, 'Fishing for Opportunities: Successful Clinical Trials Management', Pharmaceutical Executive (1 June 2006), available at , accessed 6 June 2007.
120. J. Enriquez, 'Might a bell toll for US Pharma?', in Progressions 2006. Capturing global Advantage in the Pharmaceutical Industry (New York: Ernst and Young Global Pharmaceutical Centre 2006) pp. 65-66.
121. R. D. Smith, 'Foreign Direct Investment and Trade in Health Services: A Review of the Literature', Social Science and Medicine 59 (2006) pp. 2313-2323.
122. A. Petryna, 'Globalizing Human Subjects Research', in A. Petryna (ed.), A. Lakoff and A. Kleinman, Global Pharmaceuticals: Ethics, Markets, Practices, (Durham: Duke University Press 2006) pp. 33-60.
123. A. T. Kearney, Making Your Move: Taking Clinical Trials to The Best Location (New York: AT Kearney Inc. 2007), available at , accessed 13 June 2007.
124. 'China Rapidly Developing Biotechnology and Bioindustry', Xinhua News Agency, Beijing (4 Jan. 2003).
125. Quoted by L. Zhenzhen et al., 'Health Biotechnology in China: Reawakening of a Giant', Nature Biotechnology 22, Supplement (2004) p. DC15.
126. K. Bound, India: The Uneven Innovator (London: Demos (2007) p. 12.
127. 'China's Generic Drugmakers Challenge India', Business Week (24 Sept. 2007), available at , accessed 6 June 2008.
128. C. Leadbetter and J. Wilsdon, The Atlas of Ideas: How Asian Innovation Can Benefit Us All (London: Demos 2007).
129. National Science Board (note 88) pp. A5-51.
130. M. Fitzgerald (2006), 'Where the Money Is', Nature Biotechnology 24 pp. 240-242.
131. B. Clark, Life Sciences Partnering China and Europe (London 11 Oct. 2006), available at , accessed 6 June 2007.
132. Ernst and Young, Transition. Global Venture Capital Insights Report 2006 (New York: Ernst and Young 2006).
133. Ministry of Science and Technology of the People's Republic of China, Agreement on Developmental Financial Cooperation in Support of Indigenous Innovation Signed Between Ministry of Science and Technology and China Development Bank Press Release (23 March 2006), available at , accessed 4 June 2006.
134. The China Development Bank is a 'policy bank' owned and operated by the national government.
135. S. Q. Wang and C. G. Wang, Report on the Development of Venture Investment of 2002 (Beijing: China Financial and Economical Publishing House 2002).
136. UK Stem Cell Initiative, Global Positions in Stem Cell Research. China. (London: Department of Health 2005), available at , accessed 9 May 2007.
137. S. Sethi, 'Venture Capital Reforms: Give Me More on the Platter', The Economic Times (31 Jan. 2001).
138. S. Chaturvedi, Dynamics of Biotechnology Research and Industry in India: Statistics, Perspectives and Key Policy Issues. Statistical Analysis of Science, Technology and Industry Working Paper 2005/6. Directorate for Science, Technology and Industry, OECD, 41 (2005), available at .
139. Ernst and Young, Transition (note 130).
140. S. Goodall, B. Janssens, K. Wagner, J. Wong, W. Woods, and M. Yeh, 'The Promise of the East: India and China as R & D Options', Nature Biotechnology 24/9 (2006) p. 1064.